Monthly information related to total number of voting rights and shares composing the share capital – May 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 2 6 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
ERYTECH’S COMBINED SHAREHOLDERS’ MEE TING ON JUNE 25, 2021 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting SS RELEASE Lyon (France), May 25 , 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1 Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET TRY b eCA-1, Phase 3 clinical trial in 2 n d line pancreatic cancer, fully enrolled, and on track for final results
ERYTECH Announces $ 30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting F irst step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the
ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose -l imiting t oxicity reported in the first dose cohor t Encouraging clinical activity observed in first patients Trial will be escalated to the next dose
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
